Flerie
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm… Read more
Flerie - Asset Resilience Ratio
Flerie (FLERIE) has an Asset Resilience Ratio of 7.39% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2024)
This chart shows how Flerie's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Flerie's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr311.90 Million | 7.39% |
| Total Liquid Assets | Skr311.90 Million | 7.39% |
Asset Resilience Insights
- Limited Liquidity: Flerie maintains only 7.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Flerie Industry Peers by Asset Resilience Ratio
Compare Flerie's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Flerie (2024–2024)
The table below shows the annual Asset Resilience Ratio data for Flerie.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.39% | Skr311.90 Million | Skr4.22 Billion | -- |